Payment overview · 2025
General Payments
$99,314.00
323 reported records · 24 companies
Healthcare provider profile · identity verified
Hayden Long, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · MOBILE, AL · NPI 1700093598
Verified facts
What the public records show
CMS Open Payments records show Hayden Long, MD received $99,314.00 in general payments during 2025 across 323 reported records.
ABBVIE INC. accounted for 96.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuplazid by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vumerity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95,922.09 | 96.6% | 176 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $655.79 | 0.7% | 20 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$395.31 | 0.4% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $341.84 | 0.3% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $264.26 | 0.3% | 21 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $248.24 | 0.2% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $236.12 | 0.2% | 12 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $206.10 | 0.2% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $181.41 | 0.2% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $171.40 | 0.2% | 10 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $139.41 | 0.1% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $85.30 | 0.1% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $75.85 | 0.1% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $69.94 | 0.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.59 | 0.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.74 | 0.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $44.08 | 0.0% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $37.49 | 0.0% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$27.81 | 0.0% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.33 | 0.0% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $22.44 | 0.0% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $19.63 | 0.0% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $18.62 | 0.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.21 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $87,925.00 | 31 |
| Food and Beverage | $6,189.39 | 259 |
| Travel and Lodging | $5,122.62 | 32 |
| Education | $76.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $77,125.51 | 136 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57,145.48 | 105 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $289.47 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $264.26 | 21 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $264.26 | 21 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $255.41 | 11 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $248.70 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $248.24 | 9 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $236.12 | 12 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $206.10 | 8 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $182.28 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $181.41 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $152.02 | 8 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $150.75 | 9 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $127.17 | 8 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $120.43 | 7 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $104.38 | 7 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $100.87 | 6 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $85.30 | 4 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $75.85 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $69.94 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $44.74 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 95 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 79 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 82 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
82 | 28 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
95 | 31 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 467 | 146 |
| Donepezil Hcl | Donepezil Hcl | 425 | 144 |
| Duloxetine Hcl | Duloxetine Hcl | 323 | 96 |
| Gabapentin | Gabapentin | 314 | 96 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 167 | 57 |
| Levetiracetam Er | Levetiracetam | 163 | 43 |
| Levetiracetam | Levetiracetam | 161 | 49 |
| Primidone | Primidone | 108 | 30 |
| Pregabalin | Pregabalin | 96 | 34 |
| Nurtec Odt | Rimegepant Sulfate | 95 | 31 |
| Ubrelvy | Ubrogepant | 82 | 28 |
| Qulipta | Atogepant | 79 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 24 |
| Clonazepam | Clonazepam | 72 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | 19 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 68 | 23 |
| Oxcarbazepine | Oxcarbazepine | 67 | 16 |
| Topiramate | Topiramate | 63 | 16 |
| Lacosamide | Lacosamide | 59 | 15 |
| Aimovig Autoinjector | Erenumab-Aooe | 58 | 13 |
| Phenobarbital | Phenobarbital | 58 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 54 | 23 |
| Carbamazepine Er | Carbamazepine | 54 | 12 |
| Sertraline Hcl | Sertraline Hcl | 54 | 18 |
| Propranolol Hcl | Propranolol Hcl | 53 | 16 |
| Rivastigmine | Rivastigmine Tartrate | 48 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | 16 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 46 | suppressed |
| Lamotrigine | Lamotrigine | 45 | 11 |
| Zonisamide | Zonisamide | 43 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 18 |
| Emgality Pen | Galcanezumab-Gnlm | 42 | 14 |
| Amantadine | Amantadine Hcl | 37 | 11 |
| Briviact | Brivaracetam | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 33 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 29 | suppressed |
| Azathioprine | Azathioprine | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Galantamine Er | Galantamine Hbr | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Xcopri | Cenobamate | 23 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Quviviq | Daridorexant Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 15 | suppressed |
| Topiramate Er | Topiramate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Gocovri | Amantadine Hcl | 14 | suppressed |
| Lamictal | Lamotrigine | 14 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Vumerity | Diroximel Fumarate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $99,314.00 · 323 records | ABBVIE INC. | AJOVY, AMYVID, Albuked, BOTOX, Briviact, EMGALITY, EPIDIOLEX, Fintepla, GAMMAKED, HYQVIA, KEDRAB, KESIMPTA, KISUNLA, KOATE, Leqembi, NEURACEQ, NUPLAZID, NURTEC ODT, Nayzilam, QULIPTA, REXULTI, Radicava, RhoGAM Ultra-Filtered PLUS, SX-ONE MICROKNIFE, TRINTELLIX, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, ZAVZPRET, Zilbrysq | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error